Interactome Biotherapeutics

Interactome Biotherapeutics develops a next-generation therapeutic platform using engineered small extracellular vesicles ("Nanovate") derived from progenitor cells to deliver diverse therapeutic payloads—including nucleic acids, proteins/peptides, small molecules—targeting diseases with high unmet need in neurology such as neuropathic pain and ALS. Their lead asset IB001 has shown promising preclinical results enhancing neural repair mechanisms and modulating inflammation. The company’s broader secretome-based approach leverages hundreds of bioactive factors for regenerative medicine applications across neurology and potentially cardiology/oncology. They are currently preclinical with IND-enabling studies underway.